pH响应性PTEN/PLGA-(HE)<sub>10</sub>-MAP纳米粒的构建及体外评价

雍琴; 岳瀚勋; 石敏; 黄仕琴; 赵轩; 余娴

doi:10.11665/j.issn.1000-5048.20210306

pH响应性PTEN/PLGA-(HE)₁₀-MAP纳米粒的构建及体外评价

1.
重庆医科大学附属第二医院Ⅰ期临床试验研究室，重庆 400010
2.
漯河市中心医院药学部，漯河 462000
3.
重庆市江津区中心医院药学部，重庆 402260

基金项目: 国家自然科学基金资助项目(No.82072327)

计量
- 文章访问数: 152
- HTML全文浏览量: 15
- PDF下载量: 724
出版历程
- 收稿日期: 2020-11-29
- 修回日期: 2021-05-25
- 刊出日期: 2021-06-24

Construction and in vitro evaluation of pH-responsive and tumor-targeted PTEN/PLGA-(HE)₁₀-MAP nanoparticles

1.
Phase I Clinical Trial Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010
2.
Department of Pharmacy, Central Hospital of Luohe, Luohe 462000
3.
Department of Pharmacy, Central Hospital of Jiangjin District, Chongqing 402260, China

Funds: This study was supported by the National Natural Science Foundation of China (No. 82072327)

摘要

摘要: 构建一种pH响应性细胞穿膜肽（cell-penetrating peptides，CPPs）修饰的载抑癌基因第10号染色体同源缺失性磷酸酯酶-张力蛋白（PTEN）质粒DNA的纳米粒PTEN/PLGA-（HE）₁₀-MAP，探讨其基因递送和体外靶向抗肿瘤作用。采用双乳化-溶剂挥发法制备载PTEN质粒DNA的聚乳酸-羟基乙酸共聚物（PLGA）纳米粒PTEN/PLGA；利用酰胺缩合反应将pH响应性组氨酸-谷氨酸（HE）重复寡肽与模型两亲性多肽（MAP）的重组体（HE）₁₀-MAP偶联至PLGA纳米粒表面，得到纳米粒PTEN/PLGA-（HE）₁₀-MAP。以粒径、Zeta电位以及包封率与载药量为指标对其进行表征分析；通过考察其细胞毒性、细胞摄取，以及靶向转染真核表达质粒和抗肿瘤细胞增殖的能力，分析其作为目的基因靶向递送系统的可行性。结果显示，制备的纳米粒粒径为（266.5 ± 2.86） nm，包封率为（80.6 ± 6.11）%，在pH 7.4、7.0和6.5条件下Zeta电位分别为-（6.7 ± 0.26） mV、 +（0.7 ± 0.22） mV和+（37.5 ± 0.85） mV；未载质粒DNA的空载体纳米粒PLGA-（HE）₁₀-MAP在肿瘤和正常细胞中的细胞毒性试验显示细胞存活率均在80%以上，制备的纳米粒可以被细胞摄取表达，且具有pH靶向抑制肿瘤细胞增殖的作用，在肿瘤的基因治疗中具有一定的应用前景。
- 纳米粒 /
- pH响应 /
- PLGA /
- 肿瘤靶向 /
- 细胞穿膜肽 /
- 基因递送
Abstract: To construct PTEN/PLGA-(HE)₁₀-MAP nanoparticles, which encapsulated PTEN plasmid DNA and combined with the pH-responsive cell-penetrating peptides (CPPs), and to investigate their effects of gene delivery and anti-tumor targets in vitro. Poly (lactic-co-glycolic acid) (PLGA) nanoparticles loaded with PTEN plasmid DNA were prepared by double emulsification-solvent evaporation method. PTEN/PLGA-(HE)₁₀-MAP nanoparticles were prepared by coupling the histidine-glutamic acid-model amphipathic peptide nanocomplex [(HE)₁₀-MAP] to the surface through amide condensation reaction. Particle size, Zeta potential, encapsulation rate and drug loading were tested to characterize the nanoparticles. By analyzing the cytotoxicity, cellular uptake, targeted transfection of eukaryotic expression plasmids and anti-tumor cell proliferation, the feasibility as a targeted gene delivery system were evaluated. The particle size of PTEN/PLGA-(HE)₁₀-MAP nanoparticles was (266.5 ± 2.86) nm, with the encapsulation efficiency (80.6 ± 6.11)%. Zeta potentials were -(6.7 ± 0.26) mV, +(0.7 ± 0.22) mV and +(37.5 ± 0.85) mV at pH 7.4, 7.0 and 6.5, respectively. In the cytotoxicity test, the cell survival rates of tumor and normal cells were above 80%.Non-loading PLGA-(HE)₁₀-MAP nanoparticles showed no obvious cytotoxicity. The results of cellular uptake experiments showed that PTEN/PLGA-(HE)₁₀-MAP nanoparticles were more readily taken up by cells.The results of CCK-8 showed that the nanoparticles could pH-specifically inhibit proliferation of tumor cell in vitro.And PTEN/PLGA-(HE)₁₀-MAP nanoparticles may be applied in tumor gene therapy.
- nanoparticle /
- pH-responsive /
- PLGA /
- tumor-targeted /
- cell-penetrating peptides /
- gene delivery

HTML全文

参考文献(26)

[1]	. CA Cancer J Clin，2021，71（3）：209-249.
[2]	Bromma K，Chithrani DB. Advances in gold nanoparticle-based combined cancer therapy［J］. Nanomaterials （Basel），2020，10（9）：E1671.
[3]	Oliver R. Principles and practice of the biologic therapy of cancer （third edition）［J］. Br J Cancer，2002，86（4）：662-663.
[4]	Li J，Yen C，Liaw D，et al. PTEN，a putative protein tyrosine phosphatase gene mutated in human brain，breast，and prostate cancer［J］. Science，1997，275（5308）：1943-1947.
[5]	Yu X，Li TT，Xia YF，et al. Herpes simplex virus type 1 VP22-mediated intercellular delivery of PTEN increases the antitumor activity of PTEN in esophageal squamous cell carcinoma cells in vitro and in vivo［J］. Oncol Rep，2016，35（5）：3034-3040.
[6]	Sun ZG，Ji N，Bi MM，et al. Negative expression of PTEN identifies high risk for lymphatic-related metastasis in human esophageal squamous cell carcinoma［J］. Oncol Rep，2015，33（6）：3024-3032.
[7]	Li X，Guo S，Min L，et al. miR-92a-3p promotes the proliferation，migration and invasion of esophageal squamous cell cancer by regulating PTEN［J］. Int J Mol Med，2019，44（3）：973-981.
[8]	Kormann MS，Hasenpusch G，Aneja MK，et al. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice［J］. Nat Biotechnol，2011，29（2）：154-157.
[9]	Liu HY，Li LF，Xu CX，et al. Preparation of pitavastatin-loaded poly lactic-co-glycolic acid nanoparticles and their effects on proliferation of endothelial progenitor cells［J］. J China Pharm Univ（中国药科大学学报），2016，47（2）：166-170.
[10]	Ratzinger G，Agrawal P，K?rner W，et al. Surface modification of PLGA nanospheres with Gd-DTPA and Gd-DOTA for high-relaxivity MRI contrast agents［J］. Biomaterials，2010，31（33）：8716-8723.
[11]	Steiner V，Sch?r M，B?rnsen KO，et al. Retention behaviour of a template-assembled synthetic protein and its amphiphilic building blocks on reversed-phase columns［J］. J Chromatogr，1991，586（1）：43-50.
[12]	Zaro JL，Fei LK，Shen WC. Recombinant peptide constructs for targeted cell penetrating peptide-mediated delivery［J］. J Control Release，2012，158（3）：357-361.
[13]	Yu X，Xu Z，Lei J，et al. VP22 mediates intercellular trafficking and enhances the in vitro antitumor activity of PTEN［J］. Mol Med Rep，2015，12（1）：1286-1290.
[14]	Huang SQ，Shi M，He YN，et al. Construction and in vitro evaluation of DC-targeted aptamer-modified Pseudomonas aeruginosa DNA vaccine delivery system［J］. J China Pharm Univ（中国药科大学学报），2019，50（6）：743-752.
[15]	Jensen DK，Jensen LB，Koocheki S，et al. Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA［J］. J Control Release，2012，157（1）：141-148.
[16]	Yang N，Jiang Y，Zhang HF，et al. Active targeting docetaxel-PLA nanoparticles eradicate circulating lung cancer stem-like cells and inhibit liver metastasis［J］. Mol Pharm，2015，12（1）：232-239.
[17]	Shen M，Huang Y，Han L，et al. Multifunctional drug delivery system for targeting tumor and its acidic microenvironment［J］. J Control Release，2012，161（3）：884-892.
[18]	Tahara K，Sakai T，Yamamoto H，et al. Establishing chitosan coated PLGA nanosphere platform loaded with wide variety of nucleic acid by complexation with cationic compound for gene delivery［J］. Int J Pharm，2008，354（1/2）：210-216.
[19]	Peres C，Matos AI，Conniot J，et al. Poly（lactic acid）-based particulate systems are promising tools for immune modulation［J］. Acta Biomater，2017，48：41-57.
[20]	Felber AE，Dufresne MH，Leroux JC. pH-sensitive vesicles，polymeric micelles，and nanospheres prepared with polycarboxylates［J］. Adv Drug Deliv Rev，2012，64（11）：979-992.
[21]	Sarko D，Beijer B，Garcia Boy R，et al. The pharmacokinetics of cell-penetrating peptides［J］. Mol Pharm，2010，7（6）：2224-2231.
[22]	Fei L，Yap LP，Conti PS，et al. Tumor targeting of a cell penetrating peptide by fusing with a pH-sensitive histidine-glutamate co-oligopeptide［J］. Biomaterials，2014，35（13）：4082-4087.
[23]	Kenien R，Zaro JL，Shen WC. MAP-mediated nuclear delivery of a cargo protein［J］. J Drug Target，2012，20（4）：329-337.
[24]	Patel VR，Agrawal YK. Nanosuspension：an approach to enhance solubility of drugs［J］. J Adv Pharm Technol Res，2011，2（2）：81-87.
[25]	Adegoke O，Park EY. Gold nanoparticle-quantum dot fluorescent nanohybrid：application for localized surface plasmon resonance-induced molecular beacon ultrasensitive DNA detection［J］. Nanoscale Res Lett，2016，11（1）：523.
[26]	Vercauteren D，Rejman J，Martens TF，et al. On the cellular processing of non-viral nanomedicines for nucleic acid delivery：mechanisms and methods［J］. J Control Release，2012，161（2）：566-581.